Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$12.23 USD
+0.21 (1.75%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $12.22 -0.01 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Income Statements
Fiscal Year end for Astria Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 83 | 54 | 195 | 37 | 27 |
Income After Depreciation & Amortization | -83 | -54 | -195 | -37 | -27 |
Non-Operating Income | 10 | 2 | 0 | 0 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -73 | -52 | -195 | -37 | -26 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -73 | -52 | -195 | -37 | -26 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -73 | -52 | -195 | -37 | -26 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -83 | -54 | -195 | -37 | -27 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -83 | -54 | -195 | -37 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 30.12 | 14.62 | 8.93 | 3.06 | 1.87 |
Diluted EPS Before Non-Recurring Items | -2.42 | -3.55 | -24.58 | -12.18 | -14.10 |
Diluted Net EPS (GAAP) | -2.42 | -3.55 | -24.58 | -12.18 | -14.10 |
Fiscal Year end for Astria Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 28.80 | 24.15 | 19.00 | 20.24 | 15.10 |
Income After SG&A, R&D, and Dept/Amort Expenses | -28.80 | -24.15 | -19.00 | -20.24 | -15.10 |
Non-Operating Income | 4.63 | 4.22 | 2.79 | 2.51 | 2.54 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -24.17 | -19.93 | -31.41 | -17.73 | -12.57 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -24.17 | -19.93 | -31.41 | -17.73 | -12.57 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -24.17 | -19.93 | -31.41 | -17.73 | -12.57 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 56.49 | 52.30 | 33.42 | 28.04 | 28.02 |
Diluted EPS Before Non-Recurring Items | -0.43 | -0.38 | -0.86 | -0.63 | -0.45 |
Diluted Net EPS (GAAP) | -0.43 | -0.38 | -0.94 | -0.63 | -0.45 |